by JCI The Journal of Clinical Investigation
Researchers believe that engineering chimeric antigen receptor (CAR) T cells to recognize CD155 is a novel approach that could be appropriate for both hematologic and solid tumors.
by Blood Advances
Fludarabine is valued for its role in chimeric antigen receptor (CAR) T-cell therapy, but scientists believe moving away from fixed dosages could mediate better outcomes.
by Blood
Research upholds the continued clinical value of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with Hodgkin lymphoma at a time when checkpoint inhibitors (CPIs) are...
by Nature
Older adults preparing for allogeneic hematopoietic stem cell transplantation (allo-HSCT) may benefit from lower doses of fludarabine during reduced-intensity conditioning (RIC), researchers say.
by ASTCT Talks
In this episode of ASTCT Talks, Dr. Corey Cutler sits down with Dr. Ana Barata to discuss the critical role of physician-patient communication in GVHD and stem cell transplantation.
by Science
Researchers present evidence, collected from several tumor models in mice, demonstrating the benefits of inhibition of interferon γ (IFN-γ) signaling in the setting of both hematologic and solid...